Please try another search
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Martin Brygger Moller | - | 2021 | Independent Chairman of the Board |
Jorgen Vilhelm Lovenorn Bardenfleth | 68 | 2018 | Independent Vice-Chairman of the Board |
Palle Christophersen | 65 | - | Member of Scientific Advisory Board |
Susan E. Bates | - | - | Member of Scientific Advisory Board |
Richard L. Schilsky | 72 | 2021 | Member of Clinical Advisory Board |
Martine Jannigje van Vugt | - | 2022 | Independent Director |
Thomas T. W. Seufferlein | - | 2021 | Member of Clinical Advisory Board |
Eric Van Cutsem | - | 2021 | Member of Clinical Advisory Board |
Josep Tabernero | - | 2021 | Member of Clinical Advisory Board |
Keld Flintholm Jorgensen | 52 | 2022 | Independent Director |
Alejandra Maria Cristina Bonifacini Mork | 62 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review